Saturday 17 October 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.9% and free cash flow grew 76.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.38
0.03
−7.32%
Follow TNYA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(96.44%) | (83.84%) | (73.59%) | (121.86%) | |
| (76.77%) | (67.90%) | (59.50%) | (95.61%) | ||
ROIC |
(228.78%) | (256.77%) | (212.08%) | 0.00% | |
Return on Tangible Assets |
(121.67%) | (76.89%) | (78.50%) | (148.41%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.45) | (0.45) | (0.30) | (0.24) | |
Free Cash Flow |
(73.47) | (68.88) | (64.63) | (52.59) | |
Capital Expenditures |
(0.75) | (0.62) | (0.25) | (0.26) | |
| Other line items | |||||
Cash ROIC |
(52.79%) | (30.78%) | (34.55%) | (35.65%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.75 | 0.78 | 0.51 | |
Depreciation/Fixed assets |
0.30 | 0.32 | 0.31 | 2.91 | |
Capex/Depreciation |
(0.09) | (0.07) | (0.03) | (0.04) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.45) | (0.30) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates